Abstract: A handle assembly has a handle, a handle spigot to which the handle is attached, a biasing member to bias the handle to a naturally closed position, an operating plate which is rotatable by the handle spigot, a mounting stock, and a housing, the spigot, the biasing member, operating plate and a majority of the mounting stock being positioned within the housing, the mounting stock being securable to the housing to hold all the components within the housing. In this manner, the handle assembly can be made as a “complete” unit with all the internal components being in position and with the handle being rotatably attached relative to the housing. Thus, no separate rose is required. Another advantage is that the unit can be assembled using a substantially concealed fixing arrangement to improve security and also to improve the aesthetic appeal of the assembly.

Abstract: The present invention concerns novel 2 amino pyrimidine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as harmaceuticals.

Abstract: Compounds of the general formula (I) are described wherein R1 and R2, which may be the same or different, is each a hydrogen atom or a CF3, CF2H or CFH2 group, provided that when one of R1 and R2 is a hydrogen atom, then the other is a CF3, CF2H or CFH2 group, and the salts, solvates or hydrates thereof. Compounds of the invention are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. Compounds of the invention may be expected to be of use in medicine, especially where the avoidance of side effects, such as joint pain, is desired.

Abstract: A mixture of a citrus agent which contains, for example, a bioflavenoid, and caprylic acid acts synergistically to treat plants by providing anti-bacterial and anti-fungal protection to plants. In a preferred embodiment, a micro-nutrient is added to the mixture to simulate plant growth, while continuing to provide the stated protection to plants.

Abstract: Pharmacologically active compounds are provided as well as pharmaceutical compositions and methods for treating cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration in a mammal.

Abstract: A compound of formula (I) wherein: R1 and R2, which may be the same or different, is each a hydrogen atom or a CF3, CF2H or CFH2 group, provided that when one of R?1 or R2 is a hydrogen atom the other is a CF3, CF2H or CFH2 group; and the salts, solvates or hydrates thereof. The compounds are potent MMP inhibitors which advantageously do not cause tendonitis in a relevant animal model. The compounds may be expected to be of use in medicine, especially where the avoidance of side effects such as joint pain is desired.

Abstract: The invention relates to hydroxamic and carboxylic acid derivatives.

Abstract: Compounds having therapeutic utility are of formula (I)

Abstract: The invention relates to hydroxamic and carboxylic acid derivatives. Compounds of the formula: are disclosed. These compounds are useful for the treatment of diseases mediated by inhibitors of matrix metalloproteinase, ADAM, ADAM-TS enzymes, and/or TNF&agr;-mediated diseases including degenerative diseases and certain cancers.

Abstract: 4-(4-(-Chlorophenyl)piperazin-1-yl)sulfonylmethyl)-tetrahydor yran-4-carboxylic acid and the corresponding N-hydroxy amide, and derivatives thereof, are useful as therapeutic agents.

Abstract: Compounds having therapeutic utility are of formula (I) B—X—(CH2)n—CR2R3—CR4R5—COY  (I) wherein n=0-1; X is S(O)0-2; Y is OR1 or NHOH; R2 and R4 are independently H or a group (optionally substituted with R10) selected from C1-6 alkyl, C2-6 alkenyl, aryl, C1-6 alkyl-aryl, heteroaryl, C1-6 alkyl-heteroaryl, heterocycloalkyl, C1-6 alkyl-heterocycloalkyl, cycloalkyl and C1-6 alkyl-cycloalkyl; and R1, R3 and R5 are independently H or C1-6 alkyl, provided that not more than two of R2, R3, R4 and R5 are H; or any of CR2R3, CR4R5 and CR2—CR4 is a cycloalkyl or heterocycloalkyl ring optionally substituted with R10 or a group (optionally substituted with R10) selected from C1-6 alkyl, aryl, C1-6 alkyl-aryl, heteroaryl and C1-6 alkyl-heteroaryl; B is heterocycloalkyl (optionally substituted by R6 or R7) bonded through carbon to X, or C1-6 alkyl-heterocycloalkyl (optionally substituted with R6 or R7), or a group (substituted with R6) selected from C1-8 alkyl

Abstract: Compounds having therapeutic utility are of formula (I)

Abstract: Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity.

Abstract: Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity.

Abstract: Pharmacologically active compounds are provided as well as pharmaceutical compositions and methods for treating cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration in a mammal.

Abstract: The invention relates to hydroxamic and carboxylic acid derivatives.

Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF &agr; or a condition involving a membrane-shedding event that is mediated by a metalloproteinase.

Abstract: Pharmacologically active compounds are provided as well as pharmaceutical compositions and methods for treating cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration in a mammal.

Abstract: Compounds of the formula (B)2N—X—(CH2)n—CR1R2—CO—Y  (I) have therapeutic utility as inhibitors of metalloproteinases etc.

Abstract: The invention relates to hydroxamic and carboxylic acid derivatives. Compounds of the formula: are disclosed. These compounds are useful for the treatment of diseases mediated by inhibitors of matrix metalloproteinase, ADAM, ADAM-TS enzymes, and or INF&agr;-mediated diseases including degenerative diseases and certain cancers.